EPA work plan review, 133-135 and 21-23 buildings, August 2005

NYC 9/11 Public Portal Document

Part II - Environmental Community Monitoring Plan 133-135 Greenwich & 21-23 Thames Streets Airtek Project 05-0701— Rev I August 1 1.2005

analyte: • quantity (concentration) found in sample, • units of measure (e.g., micrograms per liter, milligrams per kilogram), • detection limit with unit of measure, • analytes reported below detection limit, etc.; and • Non-conformance summary identifying any known failure to comply with the QAPP or Sampling and Analysis Plan such as the following: • exceeded holding times, • failure to achieve required detection limits, • poor surrogate recovery or poor duplicate precision, • unidentified samples or custody forms, • broken custody seals, and • uncalibrated or improperly calibrated instruments.

4.1 Laboratory Reports and Chain of Custody Forms

The laboratory will send copies of reports to the Airtek QA Officer for data validation and a copy to the Airtek Project Manager for the project files. These reports will include a copy of the Chain of Custody form. The laboratory will retain a copy of all data reports and Chain of Custody forms.

5.0 DATA VALIDATION AND QUALITY ASSURANCE AUDIT

This section outlines the procedures necessary for the data validation and quality assurance audit, which ensures the accuracy of the results.

5.1 Data Validation

Data validation is a systematic procedure of reviewing a body of data against a set of established criteria so as to provide a specified level of assurance of its validity prior to its intended use. The review of the data will include an audit of the quality control samples—the laboratory's method blanks, field blanks, spikes, and surrogate recoveries. These quality control samples allow a direct check on the variability in the methods of analysis and sampling and in the sample matrix itself. The data will be reviewed by the laboratory's QA Officer for compliance to the technical specifications and completeness. The laboratory will provide a non-conformance summary as appropriate for the analytes determined. Included in the non-conformance summary will be notification of sample receipts. This will include information regarding problems with sample packaging, Chain of Custody and sample preservation. A preliminary review for deviations from method protocols including holding times, surrogate recoveries, and spike recoveries will be reviewed.

The QA Officer will evaluate a number of criteria including the following: • Chain of Custody completeness; • Analyses completed versus analyses planned; • Time held versus holding times; • Laboratory blanks (method and instrument); • Laboratory Control Sample; • Trip and field blank results; and • Duplicate analyses precision.

NYC-WTC 000134973